DexCom (DXCM) Q3 2025 Earnings Call Transcript

DexCom reported Q3 revenue of $1.21B (+22% reported, +20% organic) and record EPS of $0.61, raised FY revenue guidance to $4.63–4.65B (~15% growth) while lowering non‑GAAP gross profit margin guidance to ~61% due to higher-than-expected manufacturing scrap. Management highlighted >$3.3B cash, plans to settle $1.2B of convertible notes in cash and continue share repurchases, G7 15‑day rollout approvals/contracts with Medicare and major payers, and Stelo exceeding $100M in its first 12 months. Operational headwinds (scrap and prior deployment complaints) pressured gross margin but are expected to improve into 2026; adjusted EBITDA and operating margin guidance are 29%–30% and 20%–21%, respectively.

Analysis

DexCom’s near-term headline noise masks two durable competitive levers: payer footprint and product mix. Extended-wear G7 variants plus software-led therapy tools (e.g., Smart Basal) change unit economics by lowering sensors-per-patient and increasing clinical stickiness; that combination materially shifts long-term gross margin geometry even if factory scrap suppresses margins in the quarters immediately ahead. Expect margin recovery to be driven more by mix (wear-time and channel) than price, which means 200–400bps of structural upside is realistic over 12–24 months if adoption follows payer/primary-care channels.

Supply-quality remediation is the principal tactical risk; the cadence for normalization will be governed by supplier requalification and factory yield curves rather than sales demand. A sustained recurrence of deployment failures would have outsized second-order effects: patient starts fall, primary-care adoption slows, and PBMs push tighter utilization management — each amplifying revenue downside within 1–6 months. Conversely, a clean launch of the 15‑day SKU and a positive basal‑titration RCT readout would convert latent covered lives into paid users and compress payor resistance, creating asymmetric upside into 2026.

The balance sheet optionality (delever / buybacks / tuck M&A) is the management lever to watch; cash allocation choices will calibrate the stock’s multiple more than quarterly margin noise. Market consensus is still oriented toward near-term operational disruption; that creates a window to take a convex position into the program launch cadence and clinical catalysts, while using short-dated protection to cap the headline-risk tail.

Key Decisions for Investors

• Directional long, DXCM equity (size 2–4% of risk capital): accumulate into any >10% pullback ahead of the broader G7 15‑day rollout and next-year RCT readouts; target 12–18 month horizon, stop-loss 20%. Rationale: asymmetric upside from sensors-per-patient mix and software-led retention if operational issues normalize.
• Yielded long-call spread, DXCM Jan‑2027 25–40% OTM call debit/credit spread: buy longer-dated call 15–25% OTM and sell nearer-term calls (3–6 months) to finance ~50–70% of premium. Timeframe 9–15 months; reward if adoption/margin recovery materializes, capped loss = net premium paid.
• Protective hedge: buy DXCM 3–9 month puts (10–20% OTM) sized to 25–50% of long exposure to guard against persistent scrap/regulatory setbacks that depress new starts. This keeps upside exposure while limiting headline-driven drawdowns in the next 6–9 months.
• Event catalyst trade (higher risk): small, tactical long vs. implied-vol sell — buy 6–12 month DXCM calls and sell 1–3 month calls before specific operational milestones (e.g., nationwide 15‑day launch windows) to capture repricing into the event; reduce position if complaint metrics re‑accelerate. Expected payoff: 1.5–3x if launches and payer uptake clear; payoff null if headline issues recur.